(Q37123500)

18 August 2017

1 reference

title

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma (English)

1 reference

18 August 2017

2

Junzo Kigawa

1 reference

18 August 2017

1

Hiroaki Itamochi

1 reference

18 August 2017

3

Naoki Terakawa

1 reference

18 August 2017

publication date

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

99

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

653-658

1 reference

Recent progress in ovarian cancer

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Survival among U.S. women with invasive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Determinants of drug response in a cisplatin-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

A family of drug transporters: the multidrug resistance-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Effects of glutathione on alkylation and cross-linking of DNA by mitomycin C. Isolation of a ternary glutathione-mitomycin-DNA adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Multiple functional domains in the adenovirus E1A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Experience with bevacizumab in the management of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

Novel therapeutic agents in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00747.X

10.1111/J.1349-7006.2008.00747.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference